Researchers of the Cancer Epigenetics group at the Josep Carreras Leukaemia Research Institute have discovered that patients with Burkitt lymphoma — a common paediatric tumour in equatorial African countries and Latin America — can be classified into two main groups based on their epigenetic signature. The study, a high-level international collaboration co-led by Dr Manel Esteller, has demonstrated that one group, HypoBL, has a milder course of the disease, whereas the other, HyperBL, is associated with early relapses and shorter survival.

New device can give peace of mind and reduce anxiety for breastfeeding moms. It uses bioimpedance, which is currently used to measure body fat, and streams clinical-grade data to a smartphone or tablet in real time. Developed by physicians and engineers, device was tested by new moms. Technology could particularly benefit fragile babies in the NICU, who have precise nutritional needs.

A review in MedComm–Biomaterials and Applications highlights how nanoparticles are revolutionizing breast cancer diagnosis and treatment. These advanced nanomaterials enhance early detection, reduce side effects, and combat drug resistance, offering promising solutions for aggressive subtypes like triple-negative breast cancer.

A research team from The University of Osaka has made a significant breakthrough in cancer radiotherapy by identifying conditions under which carbon ion beams—delivered at ultra-high dose rates (uHDR)—can protect normal cells. This phenomenon, known as the “FLASH effect,” could revolutionize cancer treatment by reducing side effects and improving patients’ quality of life.